GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (FRA:DBV1) » Definitions » Cyclically Adjusted PB Ratio

DBV Technologies (FRA:DBV1) Cyclically Adjusted PB Ratio : 0.28 (As of Jun. 03, 2025)


View and export this data going back to 2014. Start your Free Trial

What is DBV Technologies Cyclically Adjusted PB Ratio?

As of today (2025-06-03), DBV Technologies's current share price is €3.24. DBV Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €11.42. DBV Technologies's Cyclically Adjusted PB Ratio for today is 0.28.

The historical rank and industry rank for DBV Technologies's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:DBV1' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.38
Current: 0.38

During the past years, DBV Technologies's highest Cyclically Adjusted PB Ratio was 0.38. The lowest was 0.00. And the median was 0.00.

FRA:DBV1's Cyclically Adjusted PB Ratio is ranked better than
75.45% of 672 companies
in the Biotechnology industry
Industry Median: 1.475 vs FRA:DBV1: 0.38

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

DBV Technologies's adjusted book value per share data for the three months ended in Mar. 2025 was €0.129. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €11.42 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


DBV Technologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for DBV Technologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Cyclically Adjusted PB Ratio Chart

DBV Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DBV Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.28

Competitive Comparison of DBV Technologies's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, DBV Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DBV Technologies's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Cyclically Adjusted PB Ratio falls into.


;
;

DBV Technologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

DBV Technologies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.24/11.42
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DBV Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, DBV Technologies's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.129/120.3800*120.3800
=0.129

Current CPI (Mar. 2025) = 120.3800.

DBV Technologies Quarterly Data

Book Value per Share CPI Adj_Book
201112 4.304 97.800 5.298
201206 16.873 98.780 20.563
201212 14.719 99.100 17.880
201306 12.305 99.700 14.857
201312 13.492 99.800 16.274
201406 10.240 100.180 12.305
201412 29.711 99.860 35.816
201506 26.849 100.440 32.179
201512 66.774 100.040 80.350
201606 59.405 100.630 71.064
201612 49.122 100.650 58.751
201706 39.497 101.320 46.927
201712 26.358 101.850 31.153
201806 33.825 103.370 39.391
201809 0.000 103.560 0.000
201812 20.248 103.470 23.557
201906 16.201 104.580 18.649
201909 11.805 104.500 13.599
201912 18.485 104.980 21.197
202003 0.000 104.590 0.000
202006 20.406 104.790 23.442
202009 0.000 104.550 0.000
202012 15.405 104.960 17.668
202103 12.948 105.750 14.739
202106 10.804 106.340 12.230
202109 9.043 106.810 10.192
202112 7.996 107.850 8.925
202203 6.780 110.490 7.387
202206 12.310 112.550 13.166
202209 11.406 112.740 12.179
202212 9.766 114.160 10.298
202303 8.899 116.790 9.173
202306 7.887 117.650 8.070
202309 7.021 118.260 7.147
202312 6.681 118.390 6.793
202403 5.341 119.470 5.382
202406 3.819 120.200 3.825
202409 2.530 119.560 2.547
202412 1.275 119.950 1.280
202503 0.129 120.380 0.129

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


DBV Technologies  (FRA:DBV1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


DBV Technologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of DBV Technologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DBV Technologies Business Description

Traded in Other Exchanges
Address
107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

DBV Technologies Headlines

No Headlines